Some of the major news and trends captured in this week's PharmaVoice newsletter. Clickhereto subscribe to the daily newsletter.

Are biotech IPOs making a comeback?

The boom in biotechIPOsat the beginning of this decade was soon replaced by years of market hesitation. Now, although the funding environment is vastly different from the biotech bubble era of the pandemic, conditions are maturing for IPOs as a viable exit path for private drug companies, according to a panel discussion planned at the BIO International Convention in San Diego in June.panel discussion, conditions are maturing for IPOs as a viable exit path for private drug companies.

This week, we spotlight an interview with theCEOofEvommune, one of the few biotech companies that chose to go public last year despite a cold market. Its CEO explained why it was the right time for an IPO. We also looked at the world's largest private drug company, Boehringer Ingelheim, entering theGLP-1 weight-loss space.

AI ventures into women's health

Women's health has historically been a notoriously difficult area in drug development. But Insilico Medicine and Aska Pharmaceutical hope to break this impasse with artificial intelligence.

The two companiesrecently announcedplans to expand their research collaboration, aiming to combine Insilico's AI capabilities with Aska's expertise in women's health to find novel drug targets for challenging gynecological diseases such as uterine fibroids and endometriosis.

In areas with long-standing unmet medical needs, any breakthrough will be welcome. This week, we reviewed theprogressthe pharmaceutical industry has made in women's health, as well as the innovation opportunities that still exist.

The exemption channel for Trump's tariffs

Have you secured your place in President Donald Trump's tariff exemption channel? The 100% tariff on imported pharmaceuticalswill take effect in a few months, which is seen as a tough stance toward the pharmaceutical industry. But after the dust settles, many large global drug companies have actually made this high tariff rate much more manageable through negotiated agreements.

Companies that have reached onshore production agreements with the government have been able to reduce the tariff rateto 20%. If they further sign agreements under the "most favored nation" pricing scheme, they may even be exempt from tariffs entirely.

This week, we explored the potential impact of the latest tariff policies on the pharmaceutical industry and how U.S. political leverage couldreshape the competitive landscape for global drug companies。